Sector Catalyst Alert
Cannabis Stocks & ETFs for 2026
Navigating the historic Schedule III rescheduling shift and the end of the 280E tax penalty for the U.S. marijuana industry.
11 Picks Analyzed
Updated June 2026
Expert Reviewed
InvestSnips is for informational purposes only. Cannabis remains federally illegal in the United States. Investing in this sector involves extreme regulatory risk, high volatility, and significant potential for capital loss. This is not financial advice.
The cannabis sector has entered its most consequential period since the initial wave of legalization. In June 2026, the market is laser-focused on the Department of Justice’s historic move to transition marijuana from Schedule I to Schedule III of the Controlled Substances Act. This shift is not merely symbolic; it effectively dismantles the 280E tax code, which has historically prevented cannabis operators from deducting ordinary business expenses. While stable sectors like the complete list of food and beverage companies listed on u s exchanges operate under normalized tax regimes, cannabis multi-state operators (MSOs) have faced effective tax rates exceeding 70%, choking liquidity and suppressing valuations for years.
As the administrative hearing concluding in July 2026 approaches, institutional capital is finally showing signs of movement. Much like the critical hardware demand tracked in our complete list of semiconductor companies listed on u s exchanges, the cannabis investment thesis has shifted from speculative growth to a structural re-rating based on cash-flow normalization. Investors today must decide between the broad, actively managed exposure of the MSOS ETF—which uses derivative swaps to navigate current exchange listing restrictions—or picking individual industry leaders like Green Thumb Industries or Curaleaf. Understanding the roadmap from rescheduling to uplisting on the NYSE and Nasdaq is now the primary driver of alpha in this volatile asset class.
Sector Intelligence
Essential Cannabis Insights
01
The 280E Tax Unlock
Schedule III reclassification removes the 280E tax burden, allowing MSOs to deduct business expenses. This could instantly double the free cash flow of top-tier profitable operators.
02
Institutional Uplisting
U.S. MSOs currently trade on the OTC markets. Federal reform is the prerequisite for these companies to uplist to the NYSE/Nasdaq, a move that would trigger massive institutional inflows.
03
Swap Contract Structure
Due to current federal laws, U.S. cannabis ETFs like MSOS must use total return swaps rather than direct equity ownership to hold plant-touching U.S. companies.
04
Extreme Beta Profile
The sector remains high-beta. Similar to small cap aerospace and defense stocks, cannabis names can see double-digit swings based on single regulatory headlines or legislative delays.
Market Dashboard
Cannabis Stocks & ETFs Performance Comparison
| Name | Ticker | Type | Exp Ratio / PE | Yield | 1Y Return | 5Y Return | Best For |
|---|---|---|---|---|---|---|---|
| AdvisorShares Pure US Cannabis | MSOS | ETF | 0.78% | 0.00% | +61.20% | -34.50% | U.S. MSO Pure-Play |
| Green Thumb Industries | GTBIF | Stock | 24.10 | 0.00% | +18.50% | -12.40% | Fundamental Profitability |
| Innovative Industrial Prop. | IIPR | REIT | 14.20 | 6.85% | +8.40% | +12.10% | Income & Real Estate |
| Curaleaf Holdings Inc. | CURLF | Stock | N/A | 0.00% | +33.00% | -41.20% | Global Retail Footprint |
| Amplify Alternative Harvest | MJ | ETF | 0.75% | 1.10% | +24.10% | -28.90% | Global Diversification |
| Trulieve Cannabis Corp. | TCNNF | Stock | N/A | 0.00% | +10.10% | -44.15% | Medical State Dominance |
| AdvisorShares Pure Cannabis | YOLO | ETF | 0.51% | 0.00% | +57.96% | -30.81% | Aggressive US-Global Mix |
| Amplify Seymour Cannabis | CNBS | ETF | 0.76% | 0.00% | +48.20% | -31.40% | Actively Managed Picks |
| AdvisorShares MSOS 2x Daily | MSOX | ETF | 0.95% | 0.00% | +114.50% | N/A | Leveraged Day Trading |
| Canopy Growth Corp. | CGC | Stock | N/A | 0.00% | +14.20% | -82.30% | Nasdaq-Listed Speculation |
Top Selection
Best Overall ETF: MSOS
Why It Tops Our List
MSOS is the only multi-billion dollar ETF that focuses exclusively on the U.S. market. It provides institutional-grade access to the large-cap MSOs that stand to benefit most from 280E relief.
Key Stats
With $1.1 billion in AUM and a 0.78% expense ratio, it is the most liquid vehicle for betting on federal marijuana policy reform in 2026.
Best For
Investors who want a “set-and-forget” basket of U.S. cannabis leaders without the single-stock risk of managing OTC-traded equities directly.
!
One Drawback
The fund relies on total return swaps with third-party banks, introducing counterparty risk that isn’t present in traditional physical-ownership ETFs.
Deep Dive Reviews
Detailed Asset Analysis
AdvisorShares Pure US Cannabis ETF
MSOS
MSOS has established itself as the undisputed anchor of the cannabis investment space. In June 2026, it remains the only major ETF to focus strictly on U.S. plant-touching operators. Because U.S. stock exchanges currently prohibit the direct listing of plant-touching marijuana businesses, MSOS utilizes a sophisticated swap structure with major institutional banks to gain exposure to names like Green Thumb and Curaleaf. This structure is its greatest strength, providing a liquid, SEC-registered vehicle for retail and institutional investors. However, the high expense ratio and the lack of a dividend reflect the active management and derivative costs required to navigate the current federal landscape. As Schedule III implementation progresses, MSOS is the primary beneficiary of the sector’s re-rating.
Green Thumb Industries
GTBIF
Green Thumb Industries is widely regarded as the “blue chip” of the multi-state operators. While many peers have struggled with heavy debt and negative cash flows, Green Thumb has maintained consistent profitability and a robust balance sheet. This fiscal discipline positions it perfectly for the removal of Section 280E. By paying its taxes on time and avoiding the aggressive sale-leaseback strategies that have hampered competitors, GTBIF retains more of its operational cash flow. Its presence in key limited-license medical states like Florida makes it a direct beneficiary of the April 2026 rescheduling order. For investors seeking direct equity exposure with the lowest fundamental risk, GTBIF is the premier choice.
Innovative Industrial Properties
IIPR
IIPR offers a unique, indirect path to cannabis exposure. As a Real Estate Investment Trust (REIT), it provides the specialized industrial infrastructure required for large-scale cannabis cultivation. It then leases these properties back to operators under triple-net lease agreements. This model has allowed IIPR to generate significant dividends, a rarity in the cannabis sector. In 2026, rescheduling and the improved financial health of its tenants (due to 280E relief) have significantly de-risked IIPR’s portfolio. It provides a defensive, income-oriented alternative for investors who want sector exposure but prefer the legal safety and tax advantages of the REIT structure. Its 6.85% yield is a standout in a historically growth-focused category.
Curaleaf Holdings Inc.
CURLF
Curaleaf is the revenue leader of the U.S. cannabis market, boasting a retail footprint that spans 15 states and includes over 150 locations. Its strategy is focused on scale and international expansion, particularly into burgeoning medical markets in Germany and the UK. While this aggressive expansion has made the company less profitable on a net income basis compared to Green Thumb, it provides the widest exposure to consumer market-share growth. In the 2026 environment, Curaleaf is a high-beta play on the full implementation of recreational rescheduling. Its sheer size makes it a must-own for those betting on the eventual commoditization of the industry and the emergence of national cannabis brands.
Amplify Alternative Harvest ETF
MJ
MJ is the legacy fund of the cannabis world, providing broad exposure to the global industry. Unlike MSOS, MJ includes significant allocations to Canadian licensed producers and international pharmaceutical firms. While Canadian producers like Tilray and Canopy Growth have faced immense structural challenges, they offer the benefit of being listed on major U.S. exchanges like the Nasdaq. MJ also includes “ancillary” companies that provide services to the industry without touching the plant directly. This makes MJ a lower-beta choice compared to the pure U.S. MSO funds. However, its heavy 5-year drawdown of 89% serves as a stark reminder of the risks of international cannabis markets before federal reform.
Trulieve Cannabis Corp.
TCNNF
Trulieve is the dominant force in the Florida medical marijuana market, holding a nearly 50% market share in the state. This regional dominance provides a massive tailwind as Florida considers the move to full adult-use legalization. Because the April 2026 DOJ order specifically fast-tracked medical marijuana to Schedule III, Trulieve is among the most immediate beneficiaries of 280E tax relief. The stock trades at a significant discount to its intrinsic value according to many analysts, primarily due to the localized concentration of its revenue. For investors who believe Florida will remain the crown jewel of the U.S. market, Trulieve offers a highly focused and potentially explosive value play.
AdvisorShares MSOS 2x Daily Leveraged ETF
MSOX
MSOX is a sophisticated trading tool designed for short-term speculation rather than long-term holding. It seeks to provide 2x the daily performance of the MSOS ETF. In the news-driven environment of June 2026, MSOX has seen staggering 1-year returns exceeding 114% as regulatory headlines have broken in the industry’s favor. However, the costs of daily rebalancing and the effects of compounding mean that in flat or volatile markets, MSOX can lose value rapidly even if the underlying sector is relatively stable. It should be used only by experienced traders with a high tolerance for risk and a specific view on immediate regulatory catalysts.
Canopy Growth Corp.
CGC
Canopy Growth remains one of the most recognizable names in the industry, backed historically by alcohol giant Constellation Brands. While its 5-year performance has been catastrophic, the company has undergone significant restructuring to reduce its burn rate. Its primary appeal in 2026 is its “Canopy USA” strategy, which aims to execute its U.S. entry through a series of acquisitions once federal law permits. As a Nasdaq-listed stock, CGC provides a level of liquidity and institutional accessibility that the OTC-traded MSOs still lack. It remains a high-risk turnaround play that serves as a benchmark for the Canadian producer segment’s recovery.
Buyer’s Guide
The 2026 Cannabis Catalyst Roadmap
Success in cannabis investing requires a tactical understanding of the regulatory timeline. We categorize the 2026 market into three sequential catalysts. The first is the Schedule III Transition, which has already begun for medical operators following the April 2026 DOJ order. This move immediately improves the balance sheets of profitable MSOs by ending the 280E tax penalty. Much like the specialized logistics found in our list of publicly traded liquefied natural gas shipping companies, the removal of tax barriers allows for a normalization of the sector’s financial plumbing.
The second catalyst is the SAFER Banking Act, which is expected to gain momentum following the finalization of rescheduling in July 2026. This legislation would allow banks to service cannabis companies without fear of federal prosecution, drastically lowering the cost of capital. Finally, the “Holy Grail” for investors is Institutional Uplisting. Once MSOs can list on the NYSE or Nasdaq, the pool of eligible buyers expands from a few thousand retail accounts to every major mutual fund and pension plan in the world. For those looking for diversified exposure during this transition, the list of publicly traded sports companies and other consumer-facing sectors show that brand equity is built during these periods of institutionalization.
Risk Assessment
What to Watch For
Regulatory Friction
While the DOJ has issued orders, the transition to Schedule III is subject to administrative hearings and potential lawsuits from anti-legalization groups that could delay implementation for months or years.
Counterparty Risk
ETF structures like MSOS rely on total return swaps with banks. If the regulatory environment changes or a bank withdraws from the cannabis sector, the ETF could be forced to liquidate at unfavorable prices.
Capital Dilution
Many cannabis companies still carry high debt loads. Even with 280E relief, some operators may be forced to issue more shares to fund growth or pay down legacy debt, diluting current shareholders.
Price Volatility
Cannabis is a news-driven sector. A single negative headline from the DEA can cause 20-30% drawdowns in a single trading session. This is an asset class for aggressive capital only.
Expert Answers
Frequently Asked Questions
Rescheduling marijuana to Schedule III is the most significant federal policy shift in decades. For investors, it signifies the end of the 280E tax penalty, which has historically prevented companies from deducting business expenses. This change can significantly increase the free cash flow and net income of profitable cannabis operators.
Yes, Section 280E only applies to substances in Schedule I and II. Once marijuana is officially moved to Schedule III, cannabis businesses will be able to deduct standard operating expenses like rent, marketing, and payroll from their federal tax filings.
Profitable U.S. multi-state operators benefit the most. Green Thumb Industries, Trulieve, and Curaleaf stand to see the largest dollar-per-share impact because they already have significant revenue and operating expenses that were previously non-deductible.
If you want exposure to the U.S. market, MSOS is the primary choice. If you want global exposure including Canadian and international markets, MJ is the better vehicle. In the current regulatory environment, MSOS is generally considered to have higher upside potential due to U.S. rescheduling.
U.S. federal law currently prohibits U.S.-listed ETFs from owning shares in plant-touching businesses that are federally illegal. To bypass this, the fund uses derivative swap contracts with banks to capture the performance of those stocks without direct ownership.
Innovative Industrial Properties is a cannabis REIT. It owns the industrial facilities where cannabis is grown and leases them back to operators. Because it is a REIT, it must distribute 90 percent of its taxable income to shareholders, resulting in a high dividend yield.
Currently, only ancillary companies or those operating outside the U.S. (like Tilray) can list on major U.S. exchanges. U.S. plant-touching companies must wait for further federal reform, such as the SAFER Banking Act or full legalization, before uplisting becomes possible.
The SAFER Banking Act would protect banks that provide services to state-legal cannabis businesses. Legislative momentum is expected to accelerate following the finalization of Schedule III reclassification in mid-2026.
The sector has seen 80 to 90 percent drawdowns over the last five years, indicating extreme risk. However, many analysts argue that current valuations are historic lows given the impending 280E relief. Position sizing is critical for managing this volatility.
As the market has matured, many smaller funds have closed. The primary remaining vehicles for investors are MSOS, YOLO, and CNBS for standard exposure, along with MJ for global reach and MSOX for leveraged trading.
Last updated June 2026 · InvestSnips Editorial